Idiopathic ulcerative colitis and fecal calprotectin as a marker of remission
DOI:
https://doi.org/10.36557/2674-8169.2025v7n7p1282-1288Keywords:
Fecal Calprotectin, Colitis, Ulcerative, Remission InductionAbstract
This research sought articles, reviews, descriptive studies, cohort studies, and medical record analysis, whose theme brought a survey of the most recent studies in the literature regarding fecal calpronectin (FC) cutoff values indicative of clinical remission for Idiopathic Ulcerative Colitis (UC). FC was presented during this review as a potential biomarker of clinical, endoscopic, and histological remission in patients with UC. In addition, some studies have shown that the use of FC in patients being monitored for UC resulted in lower costs to the system when compared to requesting follow-up colonoscopies.
Downloads
References
- GOLDMAN, L. & AUSIELLO, D. — Cecil: tratado de Medicina Interna. 23. ed., Rio de Janeiro, Elsevier, 2005.
- TURNER, D. et al. STRIDE-II: An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology, v. 160, n. 5, p. 1570–1583, 2021.
- MAASER, C. et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. Journal of Crohn’s & colitis, v. 13, n. 2, p. 144–164, 2019.
- LEE, J.-M. et al. A comparison of diagnostic performance between two quantitative rapid fecal calprotectin assays in detecting active inflammatory bowel disease. PloS one, v. 16, n. 8, p. e0255974, 2021.
- ZITTAN, E. et al. Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic Crohn’s disease. Inflammatory bowel diseases, v. 22, n. 3, p. 623–630, 2016.
- HASSAN, E. A. et al. Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis. Saudi journal of gastroenterology: official journal of the Saudi Gastroenterology Association, v. 23, n. 4, p. 238–245, 2017.
- STEVENS, T. W. et al. Diagnostic accuracy of fecal calprotectin concentration in evaluating therapeutic outcomes of patients with ulcerative colitis. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association, v. 19, n. 11, p. 2333–2342, 2021.
- TURNER, D. et al. STRIDE-II: An update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology, v. 160, n. 5, p. 1570–1583, 2021.
- MAK, W. Y. et al. Fecal calprotectin in assessing endoscopic and histological remission in patients with ulcerative colitis. Digestive diseases and sciences, v. 63, n. 5, p. 1294–1301, 2018.
- MOTAGANAHALLI, S. et al. Faecal calprotectin delivers on convenience, cost reduction and clinical decision-making in inflammatory bowel disease: a real-world cohort study: Faecal calprotectin in IBD. Internal medicine journal, v. 49, n. 1, p. 94–100, 2019.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Raiza Lorena Batista da Silva, Janaína Franco Nara, Laura Clemente de Oliveira Neto, Elisa Alves Ramos Zin, Antônio Pedro Pinto Perez, Giulia Faria Zima, Keyla Poliana da Silva Oliveira, Gustavo Francisco Santos da Silva, João Miguel Fernandes Wouters, Rafael da Silva Franchini, Clara Gonçalves Vidal, Nicole Jezini Bittencourt, Lohana Assunção Cavalcante, Alaércio Maran Filho; Alex Moreira Souza
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors are copyright holders under a CCBY 4.0 license.
